Gabelli Analysts Decrease Earnings Estimates for Vitamin Shoppe, Inc (VSI)

Vitamin Shoppe, Inc (NYSE:VSI) – Investment analysts at Gabelli cut their FY2017 earnings per share (EPS) estimates for shares of Vitamin Shoppe in a research note issued on Thursday. Gabelli analyst D. Witkowski now anticipates that the specialty retailer will post earnings of $0.40 per share for the year, down from their previous estimate of $0.75. Gabelli also issued estimates for Vitamin Shoppe’s FY2018 earnings at $0.25 EPS, FY2019 earnings at $0.40 EPS and FY2020 earnings at $0.75 EPS.

Vitamin Shoppe (NYSE:VSI) last announced its earnings results on Wednesday, November 8th. The specialty retailer reported ($0.03) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.17 by ($0.20). The business had revenue of $288.20 million for the quarter, compared to analyst estimates of $297.61 million. Vitamin Shoppe had a positive return on equity of 6.17% and a negative net margin of 20.27%. The business’s revenue was down 8.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.50 EPS.

WARNING: “Gabelli Analysts Decrease Earnings Estimates for Vitamin Shoppe, Inc (VSI)” was originally posted by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this piece on another publication, it was stolen and republished in violation of United States & international trademark and copyright laws. The correct version of this piece can be read at https://sportsperspectives.com/2017/11/15/gabelli-analysts-decrease-earnings-estimates-for-vitamin-shoppe-inc-vsi.html.

A number of other equities analysts have also weighed in on the stock. Goldman Sachs Group, Inc. (The) reissued a “sell” rating and issued a $6.00 price objective (down previously from $13.00) on shares of Vitamin Shoppe in a research report on Thursday, August 10th. Barclays PLC cut their price objective on shares of Vitamin Shoppe from $6.00 to $3.00 and set an “equal weight” rating for the company in a research report on Thursday, November 9th. Deutsche Bank AG reissued a “hold” rating and issued a $7.00 price objective (down previously from $14.00) on shares of Vitamin Shoppe in a research report on Thursday, August 10th. TheStreet lowered shares of Vitamin Shoppe from a “c-” rating to a “d” rating in a research report on Wednesday, August 9th. Finally, Morgan Stanley cut their price objective on shares of Vitamin Shoppe from $7.50 to $4.00 and set an “equal weight” rating for the company in a research report on Thursday, November 9th. Four equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and one has given a buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $5.00.

Vitamin Shoppe (NYSE:VSI) opened at $3.60 on Monday. The company has a current ratio of 2.07, a quick ratio of 0.32 and a debt-to-equity ratio of 0.59. The stock has a market cap of $83.92, a PE ratio of 3.76 and a beta of 0.74. Vitamin Shoppe has a 52-week low of $2.95 and a 52-week high of $26.35.

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Schwab Charles Investment Management Inc. grew its stake in Vitamin Shoppe by 34.6% during the second quarter. Schwab Charles Investment Management Inc. now owns 262,123 shares of the specialty retailer’s stock worth $3,054,000 after buying an additional 67,362 shares during the period. Aperio Group LLC acquired a new position in shares of Vitamin Shoppe during the second quarter worth $402,000. Teachers Advisors LLC lifted its position in shares of Vitamin Shoppe by 4.7% during the first quarter. Teachers Advisors LLC now owns 63,691 shares of the specialty retailer’s stock worth $1,283,000 after purchasing an additional 2,887 shares in the last quarter. Goldman Sachs Group Inc. lifted its position in shares of Vitamin Shoppe by 88.5% during the second quarter. Goldman Sachs Group Inc. now owns 124,077 shares of the specialty retailer’s stock worth $1,445,000 after purchasing an additional 58,243 shares in the last quarter. Finally, Russell Investments Group Ltd. lifted its position in shares of Vitamin Shoppe by 16.7% during the second quarter. Russell Investments Group Ltd. now owns 26,788 shares of the specialty retailer’s stock worth $312,000 after purchasing an additional 3,839 shares in the last quarter. Institutional investors own 98.39% of the company’s stock.

In related news, Director John D. Bowlin bought 40,000 shares of the stock in a transaction that occurred on Friday, August 25th. The stock was purchased at an average cost of $5.50 per share, for a total transaction of $220,000.00. Following the completion of the acquisition, the director now owns 56,028 shares in the company, valued at $308,154. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.07% of the stock is currently owned by insiders.

About Vitamin Shoppe

Vitamin Shoppe, Inc (VSI) is a multi-channel specialty retailer and contract manufacturer of vitamins, minerals, herbs, specialty supplements, sports nutrition, and other health and wellness products. The Company operates through three segments: retail, direct and manufacturing. The retail segment includes Vitamin Shoppe, Super Supplements and Vitapath retail store formats.

Earnings History and Estimates for Vitamin Shoppe (NYSE:VSI)

Receive News & Ratings for Vitamin Shoppe Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vitamin Shoppe Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply